The article discusses the drug profile of trabectedin to treat patients with hepatic dysfunctions. The study was reviewed thoroughly by the independent peer researchers to make sure that the results were based on balanced analyses, objectives and free from commercial biases. Information regarding the clinical indications, pharmacokinetics and therapeutic effects of the therapy is also elaborated.